An Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCs for the Treatment of a Single Patient With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications Spinal cord injuries
- Focus Expanded access; Therapeutic Use
- 19 Sep 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2022 Status changed from suspended to active, no longer recruiting.
- 07 Apr 2021 New trial record